Bajaj Healthcare Ltd (IN:BAJAJHCARE)
:BAJAJHCARE
Want to see IN:BAJAJHCARE full AI Analyst Report?
Top Page
Bajaj Healthcare Ltd
(BAJAJHCARE)
Select Model
Select Model
Rating:53Neutral
Price Target:
₹338.00
▼(-19.24% Downside)
Action:ReiteratedDate:03/19/26
The score is primarily held back by mixed financial performance—especially high leverage and weak/negative free cash flow—and a very bearish technical setup with the price well below key moving averages. Valuation is neutral with limited dividend support.
Positive Factors
Diversified manufacturing model (APIs, formulations, contract manufacturing)
Multiple durable revenue streams—APIs, finished dosages and contract manufacturing—reduce dependence on any single product or customer. This industrial manufacturing base supports recurring order flows, long-term customer contracts and scalable margins if utilization remains high, bolstering cash generation potential.
Negative Factors
Elevated leverage (high debt-to-equity)
High leverage reduces financial flexibility and increases refinancing and interest-rate risk. Over several quarters, elevated debt can limit capital allocation to R&D or capacity expansion, raise fixed financial costs and magnify earnings volatility if revenue or margins weaken, straining long-term stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified manufacturing model (APIs, formulations, contract manufacturing)
Multiple durable revenue streams—APIs, finished dosages and contract manufacturing—reduce dependence on any single product or customer. This industrial manufacturing base supports recurring order flows, long-term customer contracts and scalable margins if utilization remains high, bolstering cash generation potential.
Read all positive factors
Bajaj Healthcare Ltd (BAJAJHCARE) vs. iShares MSCI India ETF (INDA)
Market Cap
₹10.25B
Dividend Yield0.24%
Average Volume (3M)4.99K
Price to Earnings (P/E)20.9
Beta (1Y)1.12
Revenue Growth17.32%
EPS GrowthN/A
CountryIN
Employees1,049
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.96
Shares Outstanding31,583,252
10 Day Avg. Volume2,706
30 Day Avg. Volume4,987
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)4.64
Price to Sales (P/S)3.98
P/FCF Ratio-124.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bajaj Healthcare Ltd Business Overview & Revenue Model
Company Description
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, and supplies amino acids, nutritional supplements, and active pharmaceutical ingredients (APIs) for pharmaceutical, nutraceuticals, and food industries in India and intern...
How the Company Makes Money
Bajaj Healthcare makes money primarily by manufacturing and selling pharmaceutical products across multiple categories. Its core revenue streams typically include: (1) sales of active pharmaceutical ingredients (APIs) and pharmaceutical intermedia...
Bajaj Healthcare Ltd Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
60
Neutral
Cash Flow
50
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.74B | 5.43B | 4.73B | 6.46B | 6.79B | 6.56B |
| Gross Profit | 2.18B | 1.71B | 2.14B | 1.33B | 1.84B | 1.93B |
| EBITDA | 1.03B | 1.02B | 406.24M | 1.22B | 1.20B | 1.43B |
| Net Income | 458.42M | 394.95M | -837.93M | 430.24M | 713.86M | 831.09M |
Balance Sheet | ||||||
| Total Assets | 8.39B | 8.33B | 7.65B | 9.01B | 7.21B | 5.26B |
| Cash, Cash Equivalents and Short-Term Investments | 140.05M | 44.51M | 29.29M | 192.29M | 19.75M | 142.41M |
| Total Debt | 2.38B | 2.23B | 3.33B | 4.15B | 2.57B | 1.81B |
| Total Liabilities | 3.52B | 3.67B | 4.87B | 5.34B | 3.93B | 2.67B |
| Stockholders Equity | 4.86B | 4.66B | 2.78B | 3.68B | 3.28B | 2.58B |
Cash Flow | ||||||
| Free Cash Flow | 392.01M | -173.16M | 620.08M | -1.46B | -786.19M | -702.30M |
| Operating Cash Flow | 501.85M | -57.78M | 922.94M | -223.24M | 6.86M | 435.58M |
| Investing Cash Flow | -198.00M | -153.21M | -112.45M | -934.27M | -747.98M | -1.09B |
| Financing Cash Flow | -210.12M | 215.28M | -965.96M | 1.31B | 618.46M | 754.57M |
Bajaj Healthcare Ltd Technical Analysis
Neutral
418.50
Price Trends
331.29
Positive
367.99
Negative
416.94
Negative
Market Momentum
5.95
Negative
61.00
Neutral
85.56
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BAJAJHCARE, the sentiment is Neutral. The current price of 418.5 is above the 20-day moving average (MA) of 317.46, above the 50-day MA of 331.29, and above the 200-day MA of 416.94, indicating a neutral trend. The MACD of 5.95 indicates Negative momentum. The RSI at 61.00 is Neutral, neither overbought nor oversold. The STOCH value of 85.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:BAJAJHCARE.
Bajaj Healthcare Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹27.78B | 18.57 | ― | 0.28% | 7.19% | 82.31% | |
69 Neutral | ₹12.65B | 17.72 | ― | ― | 28.33% | 76.13% | |
67 Neutral | ₹13.36B | 28.83 | ― | 1.24% | 11.02% | -22.20% | |
61 Neutral | ₹12.74B | 38.81 | ― | 0.44% | 1.94% | 31.46% | |
60 Neutral | ₹8.91B | 22.95 | ― | 0.48% | -21.83% | -137.74% | |
53 Neutral | ₹10.25B | 20.91 | ― | 0.24% | 17.32% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:BAJAJHCARE
Bajaj Healthcare Ltd
333.00
-240.40
-41.93%
IN:BLISSGVS
Bliss Gvs Pharma Limited
273.70
152.65
126.10%
IN:HESTERBIO
Hester Biosciences Limited
1,666.95
-242.48
-12.70%
IN:JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd.
203.95
-26.21
-11.39%
IN:SYNCOMF
Syncom Formulation (India) Ltd.
14.05
-2.83
-16.77%
IN:THEMISMED
Themis Medicare Limited
97.50
-32.96
-25.26%
Bajaj Healthcare Ltd Corporate Events
Bajaj Healthcare Closes Trading Window Ahead of FY26 Results
Mar 24, 2026
Bajaj Healthcare Ltd has announced the closure of its trading window for company securities for all insiders, designated persons, and their immediate relatives from April 1, 2026. The window will remain shut until 48 hours after the release of the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.